Covis Pharma sets initial price talk in $850 million equivalent two-part secured notes offering

By Paul A. Harris

Portland, Ore., Jan. 20 – Covis Pharma set initial price talk in its $850 million equivalent two-part offering of Covis Finco Sarl five-year senior secured notes (B), according to market sources.

The deal features $375 million equivalent of euro-denominated notes with initial talk in the 7% area.

As reported, it also features a $475 million tranche of dollar-denominated notes with initial talk in the 7½% area.

The offer was scheduled to be pitched on a Thursday morning conference call with investors.

Books close at 5 p.m. ET on Jan. 26, and the deal is set to price thereafter.

Barclays is the left bookrunner. HSBC, Mizuho, MUFG, BNP Paribas and RBC are the joint bookrunners.

The Rule 144A and Regulation S for life notes come with two years of call protection.

The Zug, Switzerland-based specialty pharmaceutical company plans to use the proceeds plus a $350 million senior secured term loan B to refinance debt, including debt incurred to finance products acquired from AstraZeneca.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.